Healthy Volunteer Clinical Trial
Official title:
An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone Used as a Single-Dose Administration or a Treatment Course in Healthy Volunteers
The current Phase I clinical trial has been developed to assess the safety and tolerability of the Fluorothyazinone drug used as a single-dose administration and a treatment course in healthy volunteers. This dose-escalation trial will be conducted with sequential enrollment of volunteers.
Based on the screening results of volunteers who signed the Informed Consent Form, the
volunteers will be sequentially enrolled in three groups to receive different product doses;
the total number of volunteers receiving the product will be not less than 25 individuals. In
view of the fact that the product will be studied in humans for the first time, initially 5
volunteers will be admitted to the hospital to receive a single product dose. As soon as the
product safety is proven by the follow-up period outcomes on Day 7, the study will be
continued with the enrollment of additional 5 volunteers. They will receive a single dose of
600 mg to assess the safety and pharmacokinetics of the studied product.
After the interim safety assessment on Day 7 is completed, additional 15 volunteers will
enter the study to receive the product in a dosage regimen proposed for the use in clinical
practice.
If necessary, backup individuals (not more than 4) will be additionally enrolled in the
study. The original volunteers could be replaced only if they had not received the product;
in case where a volunteer has received the product, no replacement will take place.
All volunteers will be divided into three groups. Initially, Group I (5 volunteers) will be
included in the study. As soon as the interim results of safety tests (complete blood count,
clinical biochemical analysis, clinical urine test and clinical examination of the general
state of health) obtained on Day 7 are evaluated, the Investigator will make decision on
whether to enroll the second group (5 individuals) to assess the product used in a dose of
600 mg. After the interim safety evaluation on Day 7, additional 15 volunteers will enter the
study to receive the product in a dosage regimen proposed for use in clinical practice.
Any of the volunteers who received a dose of the studied product will be considered as a
subject enrolled in the study, and his/her data will be used for assessing the product safety
and tolerability.
The consecutive enrollment of volunteers is implied for each of the groups with an interim
assessment of the safety parameters.
The study will be composed of four (4) visits for volunteers of Group I (a screening visit,
the hospitalization visit during which a volunteer will receive the studied product and stay
for three (3) days at the hospital, and two outpatient visits - 5 and 7 days after receiving
the product).
The study will be composed of four (4) visits for volunteers of Group II (a screening visit,
the hospitalization visit during which a volunteer will receive the studied product and stay
for seven (7) days at the hospital, and two outpatient visits -14 and 28 days after receiving
the product).
The study will be composed of five (5) visits for volunteers of Group III (a screening visit,
the hospitalization visit during which a volunteer will receive the studied product and stay
for seven (7) days at the hospital, and three outpatient visits - 14, 28 and 60 days after
receiving the product).
After a volunteer signs the Informed Consent Form at the screening stage, a screening number
will be assigned to the volunteer (consecutive numbering system will be used, i.e. numbers
will be assigned to volunteers as they arrive: the first volunteer will be assigned a number
01, the second volunteer - 02, the third - 03, etc.), and appropriate notes will be made in
the Case Report Forms (CRF) and source documentation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
Not yet recruiting |
NCT06441916 -
Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT02547259 -
Influence of Emotion in a Test Run Forgetfulness
|
N/A | |
Completed |
NCT01414881 -
Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01591850 -
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
|
Phase 1 |